Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
Matthew A GreenwaldDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4765-2738
Suzanne L MeinigMarsico Lung Institute, University of North Carolina, Chapel Hill, North Carolina, USA.
Lucas M PlottMarsico Lung Institute, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-1771-642X
Cristian RocaDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-2522-0360
Matthew G HiggsDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.
Nicholas P VitkoMarsico Lung Institute, University of North Carolina, Chapel Hill, North Carolina, USA.
Matthew R MarkovetzMarsico Lung Institute, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-3931-0594
Kaitlyn R RouillardMarsico Lung Institute, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-0856-8640
Jerome CarpenterMarsico Lung Institute, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0001-7612-3363
Mehmet KesimerMarsico Lung Institute, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-3867-1873
David B HillMarsico Lung Institute, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-9270-777X
Jonathan C SchislerDepartment of Pharmacology, The University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0001-7382-2783
Matthew C WolfgangDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4534-6470
University of North Carolina at Chapel Hill · US
Funding
Vector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Richard Charles Boucher, Martina Gentzsch · 2004 to 2026
$26.5M
Project 4: Biophysical and structural characterization of airway submucosal gland mucus in health and diseaseP01HL164320 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Richard Charles Boucher, Michael Rubinstein · 2022 to 2026
$13.9M
Dual CHIP Functions Control Tau Triage In Alzheimer's DiseaseR01AG061188 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COHEN, TODD JONATHAN, SCHISLER, JONATHAN C. · 2019 to 2023
$3.1M
Protein quality control in age-related diseasesR01AG066710 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SCHISLER, JONATHAN C. · 2020 to 2024
$2.4M
Impact of hyperglycemia on the pathogenesis of chronic bacterial lung infectionR21AI174088 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THURLOW, LANCE R., WOLFGANG, MATTHEW C · 2023 to 2024
$411k
Cystic Fibrosis Foundation (CFF) HILL20Y2-OUTCystic Fibrosis Foundation (CFF) WOLFGA19G0DHAC | National Health and Medical Research Council (NHMRC) 1183640HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21AI174088HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) P30DK065988HHS | NIH | National Institute on Aging (NIA) R01AG066710, R01AG061188NHLBI NIH HHS P01 HL164320NIAID NIH HHS R21 AI174088NIA NIH HHS R01 AG061188NIA NIH HHS R01 AG066710NIDDK NIH HHS P30 DK065988
6 · The paper itself
Abstract
The airway milieu of individuals with muco-obstructive airway diseases (MADs) is defined by the accumulation of dehydrated mucus due to hyperabsorption of airway surface liquid and defective mucociliary clearance. Pathological mucus becomes progressively more viscous with age and disease severity due to the concentration and overproduction of mucin and accumulation of host-derived extracellular DNA (eDNA). Respiratory mucus of MADs provides a niche for recurrent and persistent colonization by respiratory pathogens, including IMPORTANCE: Antibiotic treatment failure in
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mucus polymer concentration and · full record | OpenQuestion